No.23-22

March 24, 2023
Eisai Co., Ltd.

EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN'S CANCER

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.

Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe (Abstract: #17). Also to be presented are data from the LEAP (**LE**nvatinib **A**nd **P**embrolizumab) clinical program analyzing tumor-response from the lenvatinib (LENVIMA®) plus pembrolizumab (KEYTRUDA®) arm of the pivotal Phase 3 Study 309/KEYNOTE-775 trial in patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting (NCT03517449; Abstract: #518).

"We look forward to sharing our data at this year's SGO Annual Meeting, particularly a new study that will be presented in an oral scientific plenary session featuring real-world outcomes in patients with recurrent or advanced endometrial cancer who were rechallenged with platinum chemotherapy," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "We believe this research is important to the healthcare providers and patients we aim to serve because it is essential to understand treatment dynamics and related outcomes in clinical practice. As a *human health care* company, we remain steadfast in our commitment to advance the science of cancer medicine through the generation of real-world evidence."

In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab. To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

The full list of Eisai presentations is included below. Full abstracts will be posted the day of scheduled presentations.

Study/Compound	Abstract Title	Abstract Type & Details (Eastern Daylight Time)
Real World Evidence		
Endometrial Cancer Non-Interventional Study	Real-world outcomes and healthcare resource utilization in recurrent or advanced endometrial cancer patients rechallenged with platinum chemotherapy in Europe	Oral Scientific Plenary Abstract #17 March 28, 2023 10:30-11:45 AM
LEAP clinical program		
Study 309/KEYNOTE-775	Characterization of tumor response with lenvatinib plus pembrolizumab in Study 309/KEYNOTE-775	Poster Discussion Abstract #518 March 27, 2023 10:40-11:20 AM

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. Eisai's Focus on Cancer

Eisai acknowledges "Oncology" as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including "tumor microenvironment", "proteostasis disruption", "cell linage and cell differentiation", and "inflammation, hypoxia, oxidative stress and cell senescence" under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these *domains* with the aim of contributing to the cure of cancers.

* KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

# # #